Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.92 - $1.38 $122,688 - $184,032
133,357 Added 13.68%
1,108,357 $1.53 Million
Q4 2023

Feb 14, 2024

BUY
$0.79 - $1.41 $770,250 - $1.37 Million
975,000 New
975,000 $1.1 Million

Others Institutions Holding CNTX

About Context Therapeutics Inc.


  • Ticker CNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,966,100
  • Market Cap $17.6M
  • Description
  • Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...
More about CNTX
Track This Portfolio

Track Opaleye Management Inc. Portfolio

Follow Opaleye Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.